Estradiol 17-beta-dehydrogenase 11 (HSD17B11)

Estradiol 17-beta-dehydrogenase 11 (HSD17B11) is an enzyme belonging to the short-chain dehydrogenase/reductase (SDR) family that catalyzes the dehydrogenation of estradiol-17-beta (EST17b) to estrone, as well as oxidation/reduction reactions involving sex hormones and fatty acids[2][3]. HSD17B11 plays a pivotal role in androgen metabolism, converting 5α-androstan-3α,17β-diol into androsterone and thereby influencing androgen availability[3]. It is expressed in a wide range of tissues—including lung, liver, pancreas, intestine, kidney, adrenal gland, heart, testis, ovary, placenta, and sebaceous gland—with particularly high levels in prostate cancer tissue[3]. HSD17B11 is transcriptionally regulated by factors such as Sp1 and C/EBPα, with cell-type specificity, and has disease relevance in various hormone-dependent tumors, especially prostate cancer and cutaneous T-cell lymphoma[3].

Other names

DHRS8PAN1BSDR16C2PSEC0029UNQ207/PRO23317-beta-HSD 1117bHSD1117betaHSD1117-beta-HSD XI17betaHSDXICTCL-associated antigen HD-CL-03retSDR2RetSDR217-BETA-HSD1117-BETA-HSDXI17-beta-hydroxysteroid dehydrogenase 1117-beta-hydroxysteroid dehydrogenase XICutaneous T-cell lymphoma-associated antigen HD-CL-03Dehydrogenase/reductase SDR family member 8Retinal short-chain dehydrogenase/reductase 2Short-chain dehydrogenase/reductase family 16C member 2CTCL tumor antigen HD-CL-03cutaneous T-cell lymphoma-associated antigen HD-CL-03

Drugs that target this enzyme would typically act as inhibitors or modulators of its dehydrogenase activity, affecting conversion rates between active and inactive androgens or estrogens[2][3].